Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 12/20 | 1.00 |
| ▸ | PSMB1 | P20618 | 5/20 | 1.00 |
| ▸ | PSMB8 | P28062 | 5/20 | 1.00 |
| ▸ | PSMB9 | P28065 | 5/20 | 1.00 |
| ▸ | PSMB10 | P40306 | 5/20 | 1.00 |
| ▸ | PSMB2 | P49721 | 5/20 | 1.00 |
| ▸ | ELANE | P08246 | 2/20 | 1.00 |
| ▸ | CTSG | P08311 | 2/20 | 1.00 |
| ▸ | CMA1 | P23946 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CNR2 | P34972 | 4/20 | 0.62 |
| ▸ | CLPP | Q16740 | 2/20 | 0.53 |
| ▸ | LONP1 | P36776 | 5/20 | 0.49 |
| ▸ | PSMB11 | A5LHX3 | 4/20 | 0.49 |
| ▸ | PSMA7 | O14818 | 4/20 | 0.49 |
| ▸ | PSMA1 | P25786 | 4/20 | 0.49 |
| ▸ | PSMA2 | P25787 | 4/20 | 0.49 |
| ▸ | PSMA3 | P25788 | 4/20 | 0.49 |
| ▸ | PSMA4 | P25789 | 4/20 | 0.49 |
| ▸ | PSMA5 | P28066 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Delanzomib SCHEMBL18331130 | 1.00 | PSMB5 (1.00) | PSMB5PSMB1PSMB8PSMB9PSMB10 | |
| Delanzomib SCHEMBL29409193 | 1.00 | PSMB5 (1.00) | PSMB5PSMB1PSMB8PSMB9PSMB10 | |
| Delanzomib SCHEMBL20408479 | 1.00 | PSMB5 (1.00) | PSMB5PSMB1PSMB8PSMB9PSMB10 | |
| Delanzomib SCHEMBL19813892 | 1.00 | PSMB5 (1.00) | PSMB5PSMB1PSMB8PSMB9PSMB10 | |
| Delanzomib SCHEMBL23651269 | 1.00 | PSMB5 (1.00) | PSMB5PSMB1PSMB8PSMB9PSMB10 | |
| Delanzomib SCHEMBL23693013 | 1.00 | PSMB5 (1.00) | PSMB5PSMB1PSMB8PSMB9PSMB10 | |
| Delanzomib SCHEMBL13386470 | 1.00 | PSMB5 (1.00) | PSMB5PSMB1PSMB8PSMB9PSMB10 | |
| Delanzomib SCHEMBL13386388 | 1.00 | PSMB5 (1.00) | PSMB5PSMB1PSMB8PSMB9PSMB10 | |
| Delanzomib SCHEMBL13386473 | 1.00 | PSMB5 (1.00) | PSMB5PSMB1PSMB8PSMB9PSMB10 | |
| Delanzomib SCHEMBL18388691 | 1.00 | PSMB5 (1.00) | PSMB5PSMB1PSMB8PSMB9PSMB10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1986 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130990-A1 | METHODS FOR IMPROVED THERAPEUTIC USE OF RECOMBINANT AAV | ULTRAGENYX PHARMACEUTICAL INC (US) | 2026-05-14 | — | — | US | claimed |
| US-20260130856-A1 | LIPOSOME COMPOSITIONS FOR DELIVERY OF COMPOUNDS AND METHODS THEREOF | NANOTECH PHARMA INC (US) | 2026-05-14 | — | — | US | claimed |
| US-20260102375-A1 | PHARMACEUTICAL COMBINATIONS FOR TREATING CANCER | PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) | 2026-04-16 | — | — | US | claimed |
| US-20260069567-A1 | Pharmaceutical Combinations For The Treatment Of Cancer | PRESAGE BIOSCIENCES, INC. (US) | 2026-03-12 | — | — | US | claimed |
| EP-4706663-A2 | FAP-ACTIVATED PROTEASOME INHIBITORS FOR TREATING SOLID TUMORS | Trustees Of Tufts College (US) | 2026-03-11 | — | — | EP | claimed |
| EP-3897625-B1 | COMPOUNDS FOR TREATING LYMPHOMA OR A T-CELL MALIGNANT DISEASE | MUNDIPHARMA INTERNATIONAL CORPORATION LTD (BM) | 2026-01-28 | — | — | EP | claimed |
| EP-4667458-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SOS1 INHIBITOR AND ANTICANCER DRUG | Kanaph Therapeutics Inc. (KR) | 2025-12-24 | — | — | EP | claimed |
| US-20250367304-A1 | FAP-ACTIVATED PROTEASOME INHIBITORS FOR TREATING SOLID TUMORS | TUFTS COLLEGE (US) | 2025-12-04 | — | — | US | claimed |
| EP-3436002-B1 | PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF CANCER | PRESAGE BIOSCIENCES INC (US) | 2025-11-05 | — | — | EP | claimed |
| EP-3897626-B1 | TINOSTAMUSTINE FOR TREATING MULTIPLE MYELOMA | MUNDIPHARMA INTERNATIONAL CORPORATION LTD (BM) | 2025-09-10 | — | — | EP | claimed |
| EP-3994132-A1 | TYROSINE KINASE NON-RECEPTOR 1 (TNK1) INHIBITORS AND USES THEREOF | Sumitomo Dainippon Pharma Oncology, Inc. (US) | 2022-05-11 | — | — | EP | claimed |
| WO-2022094262-A1 | FAP-ACTIVATED SERUM EXTENDED HALF-LIFE THERAPEUTIC CONJUGATES | AVACTA LIFE SCIENCES LIMITED (GB) | 2022-05-05 | — | — | WO | claimed |
| EP-3768265-B1 | NEW CENTRALLY-ACTIVE GHRELIN AGONIST AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2022-05-04 | — | — | EP | claimed |
| US-11320422-B2 | Inhibition of protein degradation for improved production | LONZA LTD. (CH) | 2022-05-03 | — | — | US | claimed |
| CN-114302878-A | Tyrosine kinase non-receptor 1(TNK1) inhibitors and uses thereof | 大日本住友制药肿瘤公司 | 2022-04-08 | — | — | CN | claimed |
| WO-2022032132-A1 | ADVANTAGEOUS THERAPIES FOR DISORDERS MEDIATED BY IKAROS OR AIOLOS | C4 THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | claimed |
| EP-1660507-B2 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | MILLENNIUM PHARM INC (US) | 2017-01-04 | — | — | EP | claimed |
| US-20150184246-A1 | BIOMARKERS OF RESPONSE TO PROTEASOME INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-07-02 | — | — | US | claimed |
| EP-1660507-B9 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2010-03-24 | — | — | EP | claimed |
| EP-1660507-B1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2009-08-05 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102375-A1 | PHARMACEUTICAL COMBINATIONS FOR TREATING CANCER | PSMB5, PSMD5, PSMA5 | PSMB5 1/4885PSMB1 16/4885PSMB8 32/4885 |
| US-20150184246-A1 | BIOMARKERS OF RESPONSE TO PROTEASOME INHIBITORS | PSME3, PSMB1, PSMB4 | PSMB5 19/4885PSMB1 2/4885PSMB8 21/4885 |
| US-20260130856-A1 | LIPOSOME COMPOSITIONS FOR DELIVERY OF COMPOUNDS AND METHODS THEREOF | SGMS2, SGMS1, LIPA | PSMB5 2603/4885PSMB1 1727/4885PSMB8 1379/4885 |
| US-20250367304-A1 | FAP-ACTIVATED PROTEASOME INHIBITORS FOR TREATING SOLID TUMORS | FAP, PSMA1, PSMB1 | PSMB5 16/4885PSMB1 3/4885PSMB8 18/4885 |
| US-20260069567-A1 | Pharmaceutical Combinations For The Treatment Of Cancer | BCL6, BCL6B, BCL9 | PSMB5 304/4885PSMB1 189/4885PSMB8 160/4885 |
| US-20260130990-A1 | METHODS FOR IMPROVED THERAPEUTIC USE OF RECOMBINANT AAV | ICOS, ICOSLG, LY6K | PSMB5 2120/4885PSMB1 882/4885PSMB8 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.